Loading
Life sciences · Journal article
The Lancet. Microbe
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Dengue, a mosquito-borne viral disease, is undergoing its largest surge in history, driven by climate and demographic changes. Expanding transmission has highlighted previously under-recognised populations at heightened risk of severe disease, including people with multimorbidity and immunosuppression, for whom live-attenuated vaccines are contraindicated or unlicensed. This evolving epidemiology underscores the urgent need for safe and effective treatments for dengue, particularly for those with complex risk profiles compounded by socioeconomic disadvantage. We examined ethical, regulatory, and implementation considerations to support WHO target product profile development for dengue therapeutics. Our analysis highlights the need for better characterisation of groups at risk through approaches such as enhanced surveillance; co-produced approaches for the inclusion of these groups in research prioritisation, trials, and care; and strategies to address key barriers to access for all, such as rapid diagnostics. This framework can potentially inform equitable development and delivery of countermeasures for other infectious disease threats to global health.